Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes

Journal of Molecular Medicine

Volumn 92, Issue 7, 2014, Pages 743-755

  Jörns, Anne ^a   Akin, Muharrem ^a   Arndt, Tanja ^a   Terbish, Taivankhuu ^a   Zu Vilsendorf, Andreas Meyer ^a   Wedekind, Dirk ^a   Hedrich, Hans Jürgen ^a   Lenzen, Sigurd ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Animal model; Beta cells; Prevention; Regeneration; Type 1 diabetes

Indexed keywords

C PEPTIDE; FINGOLIMOD; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR; ANTIBODY; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CELL REGENERATION; CONTROLLED STUDY; CYTOKINE RELEASE; HYPERGLYCEMIA; IMMUNOCOMPETENT CELL; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; NONHUMAN; RAT; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; CYTOLOGY; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; LYMPH NODE; PANCREAS ISLET BETA CELL; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES; CELL PROLIFERATION; CYTOKINES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; INSULIN-SECRETING CELLS; LYMPH NODES; MACROPHAGES; MICROSCOPY, ELECTRON, TRANSMISSION; PROPYLENE GLYCOLS; RATS; RECEPTORS, ANTIGEN, T-CELL; SPHINGOSINE; T-LYMPHOCYTES;

EID: 84903309761     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-014-1137-2     Document Type: Article

References (52)

1. Eisenbarth GS (2010) Type I diabetes. Molecular, cellular and clinical immunology, pp. (http://www.barbaradaviscenter.org/)
2. Todd JA (2010) Etiology of type 1 diabetes. Immunity 32:457-467
3. Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293-1300
4. von Herrath M (2010) Combination therapies for type 1 diabetes: why not now? Immunotherapy 2:289-291
5. van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91:79-118
6. Chatenoud L (2005) CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr Opin Immunol 17:632-637
7. Chatenoud L (2008) The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic. Handb Exp Pharmacol 181:221-236
8. Chatenoud L (2010) Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 6:149-157
9. Hünig T, Tiefenthaler G, Lawetzky A, Kubo R, Schlipköter E (1989) T-cell subpopulations expressing distinct forms of the TCR in normal, athymic, and neonatally TCR alpha beta-suppressed rats. Cold Spring Harb Symp Quant Biol 54(Pt 1):61-68
10. de la Hera A, Muller U, Olsson C, Isaaz S, Tunnacliffe A (1991) Structure of the T cell antigen receptor (TCR): two CD3 epsilon subunits in a functional TCR/CD3 complex. J Exp Med 173:7-17
11. Chatenoud L (2009) Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Curr Opin Organ Transplant 14:351-356
12. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54:1763-1769 (Pubitemid 40770766)
13. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598-2608 (Pubitemid 41007846)
14. Keymeulen B,Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53:614-623
15. http://www.clinicaltrials.gov/ct2/show/study/NCT01123083
16. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D et al (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378:487-497
17. Mehta DS, Christmas RA, Waldmann H, Rosenzweig M (2010) Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice. Immunology 130:103-113
18. http://www.medicalnewstoday.com/articles/218996.php
19. Bach JF (2011) Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 378:459-460
20. Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, Mandrup-Poulsen T, Herold KC (2012) Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 61:145-154
21. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K et al (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 122:1717-1725
22. Leahy JL, Hirsch IB, Peterson KA, Schneider D (2010) Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 95:4206-4216
23. Jörns A, Rath KJ, Terbish T, Arndt T, zu Vilsendorf AM, Wedekind D, Hedrich HJ, Lenzen S (2010) Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation. Endocrinology 151:3655-3666
24. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:883-897
25. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387-401
26. Lenzen S, Tiedge M, Elsner M, Lortz S, Weiss H, Jörns A, Klöppel G, Wedekind D, Prokop CM, Hedrich HJ (2001) The LEW.1AR1/Ztm-iddm rat: a new model of spontaneous insulin-dependent diabetes mellitus. Diabetologia 44:1189-1196 (Pubitemid 32835513)
27. Jörns A, Günther A, Hedrich HJ, Wedekind D, Tiedge M, Lenzen S (2005) Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. Diabetes 54:2041-2052 (Pubitemid 40911267)
28. Hünig T, Wallny HJ, Hartley JK, Lawetzky A, Tiefenthaler G (1989) A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature andmature T lymphocytes. J ExpMed 169:73-86 (Pubitemid 19035543)
29. Arndt T, Wedekind D, Weiss H, Tiedge M, Lenzen S, Hedrich H-J, Jörns A (2009) Prevention of spontaneous immune-mediated diabetes development in the LEW.1AR1-iddm rat by selectiveCD8+ T-cell transfer is associated with a cytokine shift in the pancreas draining lymph nodes. Diabetologia 52:1381-1390
30. Sempe P, Bedossa P, Richard MF, Villa MC, Bach JF, Boitard C (1991) Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur J Immunol 21:1163-1169
31. Chatenoud L, Bach JF (2005) Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance. Expert Opin Biol Ther 5(Suppl 1):S73-S81 (Pubitemid 41243347)
32. Chen G, Han G,Wang J,Wang R, Xu R, Shen B, Qian J, Li Y (2008) Essential roles of TGF-beta in anti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells. J Leukoc Biol 83:280-287 (Pubitemid 351225608)
33. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC (2007) Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 148:5136-5144 (Pubitemid 350012634)
34. Matsumoto Y, Tsuchida M, Hanawa H, Abo T (1994) Successful prevention and treatment of autoimmune encephalomyelitis by short-term administration of anti-T-cell receptor alpha beta antibody. Immunology 81:1-7 (Pubitemid 24249824)
35. Ke Y, Jiang G, Sun D, Kaplan HJ, Shao H (2011) Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-beta dependent regulatory T cells. Clin Immunol 138:311-320
36. von Herrath MG, Coon B, Wolfe T, Chatenoud L (2002) Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol 168:933-941 (Pubitemid 34049598)
37. Chatenoud L (2008) Chemical immunosuppression in islet transplantation - friend or foe? N Engl J Med 358:1192-1193
38. Boettler T, von Herrath M (2010) Immunotherapy of type 1 diabetes - how to rationally prioritize combination therapies in T1D. Int Immunopharmacol 10:1491-1495
39. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M (2010) Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF type 1 diabetes combination therapy assessment group. Clin Exp Immunol 160: 176-184
40. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M (2006) Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 116:1371-1381
41. Penaranda C, Tang Q, Ruddle NH, Bluestone JA (2010) Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes 59:1461-1468
42. Weir GC, Bonner-Weir S (2010) Dreams for type 1 diabetes: shutting off autoimmunity and stimulating beta-cell regeneration. Endocrinology 151:2971-2973
43. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC (2006) Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 55:3238-3245 (Pubitemid 44923579)
44. Dor Y, Brown J, Martinez OI, Melton DA (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41-46 (Pubitemid 38620543)
45. Bonner-Weir S, LiWC,Ouziel-YahalomL,Guo L,Weir GC, Sharma A (2010) Beta-cell growth and regeneration: replication is only part of the story. Diabetes 59:2340-2348
46. Khalaileh A, Gonen-Gross T, Magenheim J, Nir T, Porat S, Salpeter S, Stolovich-Rain M, Swisa A, Weinberg N, Dor Y (2008) Determinants of pancreatic beta-cell regeneration. Diabetes Obes Metab 10(Suppl 4):128-135
47. Schloot NC, Hanifi-Moghaddam P, Aabenhus-Andersen N, Alizadeh BZ, Saha MT, Knip M, Devendra D, Wilkin T, Bonifacio E, Roep BO et al (2007) Association of immune mediators at diagnosis of type 1 diabetes with later clinical remission. Diabet Med 24:512-520 (Pubitemid 46669316)
48. Waldron-Lynch F, von Herrath M, Herold KC (2008) Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass. Novartis Found Symp 292:143-202
49. Leavenworth JW, Ma X, Mo YY, Pauza ME (2009) SUMO conjugation contributes to immune deviation in nonobese diabetic mice by suppressing c-Maf transactivation of IL-4. J Immunol 183:1110-1119
50. Rapoport MJ, Mor A, Vardi P, Ramot Y, Winker R, Hindi A, Bistritzer T (1998) Decreased secretion of Th2 cytokines precedes up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J Autoimmun 11:635-642 (Pubitemid 29016121)
51. Zak KP, Popova VV, Mel'nichenko SV, Tron'ko EN, Man'kovskii BN (2010) The level of circulating cytokines and chemokines in the preclinical and early clinical stages of type IA diabetes mellitus development. Ter Arkh 82:10-15
52. Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO (2008) Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 105:12439-12444